A Phase 3 interventional study of Insulin icodec and Insulin Glargine 100U/mL in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 311 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 14th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Canada, Germany, Italy
Ages 18+
Xi'an International Medical Center Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,085 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 84 across the 27 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 27 have an industry lead sponsor. The 2 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 30th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2021, is one of 187 in phase 3, and was the 525th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin icodec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07747402Xi'an International Medical Center HospitalInsulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares insulin icodec to different daily insulins in people with type 2 diabetes.
The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random.
The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.
Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App.
The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken.
Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.
Drug: Insulin icodec
Participants randomised to basal insulin analogue injections once daily
Drug: Insulin Glargine 100U/mL · Drug: Insulin Degludec · Drug: Insulin Glargine 300U/mL
Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c from baseline (week 0) to week 52 is presented.
Time frame: Baseline (week 0), week 52
Time From Baseline to Treatment Discontinuation or Intensification
Time from baseline to treatment discontinuation or intensification from baseline (week 0) to week 52 is presented.
Time frame: From baseline (week 0) to week 52
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction
Change in DTSQs in total treatment satisfaction is presented. The DTSQs questionnaire was used to assess participants treatment satisfaction which contained 8 components (DTSQs Item 1-8 : how satisfied are you with your current treatment, how often have you felt that blood sugars have been unacceptably high, how often have you felt that blood sugars have been unacceptably low, how convenient have you been finding your treatment to be recently, how flexible have you been finding your treatment to be recently, how satisfied are you with your understanding of your diabetes, would you recommend treatment to someone else with your kind of diabetes, how satisfied would you be to continue with present form of treatment). The result presented is the treatment satisfaction summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Total scores for treatment satisfaction range from 0-36 with 0 being the lowest and 36 being the highest score in total treatment satisfaction.
Time frame: Baseline (week 0), week 52
Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance Domain
Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance domain at week 52 is presented. The TRIM-D questionnaire was developed to capture the impact of diabetes treatment on patients' functioning and well-being. The questionnaire was used to measure the compliance between the treatment groups. The total TRIM-D compliance score is computed by summing across the items and then transforming to a 0-100 scale with higher score indicating better compliance.
Time frame: At end of treatment (week 52)
Number of Severe Hypoglycaemic Episodes (Level 3)
Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
Time frame: From baseline (week 0) to week 57
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 Millimoles Per Liter [mmol/L] (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter)
Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 millimoles per liter \[mmol/L\] (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.
Time frame: From baseline (week 0) to week 57
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
Time frame: From baseline (week 0) to week 57
The trial was conducted at 182 sites in Canada, Germany, Greece, Hungary, Poland, Turkey and the United States.
| Milestone | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Started | 542 | 543 |
| Full analysis set (fas) | 542 | 543 |
| Safety analysis set (sas) | 542 | 538 |
| Completed | 497 | 493 |
| Not completed | 45 | 50 |
| Withdrew: Withdrawal by subject | 24 | 20 |
| Withdrew: Lost to follow-up | 14 | 19 |
| Withdrew: Physician decision | 3 | 5 |
| Withdrew: Death | 3 | 6 |
| Withdrew: Site closure | 1 | 0 |
Change in HbA1c from baseline (week 0) to week 52 is presented.
| Percentage of HbA1c | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -1.68 ± 0.09 | -1.31 ± 0.12 |
Time from baseline to treatment discontinuation or intensification from baseline (week 0) to week 52 is presented.
| Weeks | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Time From Baseline to Treatment Discontinuation or Intensification | 20.1 (0.0 to 51.0) | 13.9 (0.0 to 55.1) |
Change in DTSQs in total treatment satisfaction is presented. The DTSQs questionnaire was used to assess participants treatment satisfaction which contained 8 components (DTSQs Item 1-8 : how satisfied are you with your current treatment, how often have you felt that blood sugars have been unacceptably high, how often have you felt that blood sugars have been unacceptably low, how convenient have you been finding your treatment to be recently, how flexible have you been finding your treatment to be recently, how satisfied are you with your understanding of your diabetes, would you recommend treatment to someone else with your kind of diabetes, how satisfied would you be to continue with present form of treatment). The result presented is the treatment satisfaction summary score, which is the sum of 6 of the 8 items of the DTSQs questionnaire. Total scores for treatment satisfaction range from 0-36 with 0 being the lowest and 36 being the highest score in total treatment satisfaction.
| Score on a scale | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Change in Diabetes Treatment Satisfaction Questionnaire (DTSQs) in Total Treatment Satisfaction | 4.68 ± 0.25 | 3.90 ± 0.25 |
Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance domain at week 52 is presented. The TRIM-D questionnaire was developed to capture the impact of diabetes treatment on patients' functioning and well-being. The questionnaire was used to measure the compliance between the treatment groups. The total TRIM-D compliance score is computed by summing across the items and then transforming to a 0-100 scale with higher score indicating better compliance.
| Score on a scale | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Treatment Related Impact Measure for Diabetes (TRIM-D) Compliance Domain | 90.42 ± 0.64 | 87.37 ± 0.64 |
Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
| Episodes | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes (Level 3) | 0 | 5 |
Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 millimoles per liter \[mmol/L\] (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.
| Episodes | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 Millimoles Per Liter [mmol/L] (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) | 104 | 76 |
Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
| Episodes | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) | 104 | 81 |
Collected over From baseline week 0 to week 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Icodec | 3/542 (0.6%) | 45/542 (8.3%) | 43/542 (7.9%) |
| Once Daily Basal Insulin Analogue | 6/543 (1.1%) | 57/538 (10.6%) | 55/538 (10.2%) |
| Event | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 2/542 | 5/538 |
| Acute myocardial infarctionCardiac disorders | 4/542 | 1/538 |
| Acute kidney injuryRenal and urinary disorders | 0/542 | 3/538 |
| COVID-19 pneumoniaInfections and infestations | 2/542 | 3/538 |
| COVID-19Infections and infestations | 3/542 | 0/538 |
| Cardiac failureCardiac disorders | 3/542 | 0/538 |
| Ankle fractureInjury, poisoning and procedural complications | 0/542 | 2/538 |
| Cardiac arrestCardiac disorders | 0/542 | 2/538 |
| DeathGeneral disorders | 0/542 | 2/538 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/542 | 2/538 |
| Event | Insulin Icodec | Once Daily Basal Insulin Analogue |
|---|---|---|
| COVID-19Infections and infestations | 43/542 | 55/538 |
Full analysis set included all randomised participants.
| Age, Continuous(Years) | Insulin Icodec | Once Daily Basal Insulin Analogue | Total |
|---|---|---|---|
| Mean | 59.15 ± 10.79 | 59.39 ± 10.15 | 59.27 ± 10.47 |
| Sex: Female, Male(Participants) | Insulin Icodec | Once Daily Basal Insulin Analogue | Total |
|---|---|---|---|
| Female | 233 | 230 | 463 |
| Male | 309 | 313 | 622 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Icodec | Once Daily Basal Insulin Analogue | Total |
|---|---|---|---|
| Hispanic or Latino | 51 | 44 | 95 |
| Not Hispanic or Latino | 490 | 499 | 989 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Insulin Icodec | Once Daily Basal Insulin Analogue | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 2 | 1 | 3 |
| Asian | 28 | 19 | 47 |
| Black Or African American | 24 | 28 | 52 |
| Native Hawaiian Or Other Pacific Islander | 2 | 1 | 3 |
| Not Reported | 1 | 0 | 1 |
| White | 478 | 493 | 971 |
| Other | 7 | 1 | 8 |
Showing the first 100 of 311 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Mar 2021 to primary completion in Aug 2022, 17 months.
Results were first posted in Aug 2025, 3 years after primary completion. A results delay was requested in Aug 2023.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin icodec